Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study

PURPOSE: In REFLECT, lenvatinib demonstrated an effect on overall survival (OS) by confirmation of noninferiority to sorafenib in unresectable hepatocellular carcinoma. This analysis assessed correlations between serum or tissue biomarkers and efficacy outcomes from REFLECT. EXPERIMENTAL DESIGN: Ser...

Descripción completa

Detalles Bibliográficos
Autores principales: Finn, Richard S., Kudo, Masatoshi, Cheng, Ann-Lii, Wyrwicz, Lucjan, Ngan, Roger K.C., Blanc, Jean-Frederic, Baron, Ari D., Vogel, Arndt, Ikeda, Masafumi, Piscaglia, Fabio, Han, Kwang-Hyub, Qin, Shukui, Minoshima, Yukinori, Kanekiyo, Michio, Ren, Min, Dairiki, Ryo, Tamai, Toshiyuki, Dutcus, Corina E., Ikezawa, Hiroki, Funahashi, Yasuhiro, Evans, Thomas R. Jeffry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401497/
https://www.ncbi.nlm.nih.gov/pubmed/34108184
http://dx.doi.org/10.1158/1078-0432.CCR-20-4219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401497/
https://www.ncbi.nlm.nih.gov/pubmed/34108184
http://dx.doi.org/10.1158/1078-0432.CCR-20-4219

Ejemplares similares